Article

The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
British Journal of Haematology (Impact Factor: 4.94). 06/2008; 141(5):615-21. DOI: 10.1111/j.1365-2141.2008.07086.x
Source: PubMed

ABSTRACT The development of cytopenia in chronic lymphocytic leukaemia (CLL) patients can predict poor prognosis. All CLL patients seen in the Division of Hematology at Mayo Clinic Rochester from 1 January 1995 to 31 December 2004 (n = 1750) were evaluated for cytopenia, aetiology of cytopenia and clinical outcome. Cytopenia occurred in 423 (24.2%) patients and was attributable to CLL in 303 (17.3%) cases, with 228 (75%) of these having bone marrow (BM) failure and 75 (25%) having autoimmune disease (AID). Survival from onset of cytopenia was significantly better for patients with AID (median 9.1 years) compared to patients with BM failure (median 4.4 years, P < 0.001). Patients with AID diagnosed within 1 year of the diagnosis of CLL (n = 35) had similar survival from diagnosis compared to patients without CLL-related cytopenia (median 9.3 vs. 9.7 years, P = 0.881). Although cytopenia caused by BM failure predicted a poorer prognosis in CLL, cytopenia caused by AID was not an adverse prognostic factor. These findings suggest that patients with cytopenia due to AID cannot be meaningfully classified by the current clinical staging systems. Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients.

0 Bookmarks
 · 
98 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Immunomodulatory drugs (IMiDs) may favour autoimmune diseases (ADs) occurrence. We conducted a retrospective study to evaluate ADs occurrence among IMIDs-treated myeloma patients. Patients were grouped into three classes depending on the type of IMID used. The first group included patients treated with thalidomide (Thal) (n=474), the second group with lenalidomide (Len) (n=140), while patients in the third group were first treated with Thal followed by Len (Thal-Len) (n= 94). Absolute risk of AD was 0.4% for patients treated with Thal, 4.3% for Len, and 1.1% for Thal-Len group. ADs manifested prevalently as autoimmune cytopenias (55%), although we observed one vasculitis, one optic neuritis, one Grave's disease, and one polymiositis. ADs occurred preferentially in the first months of IMiD treatment. A previous autologous transplant was shown to be a significant risk factor. All ADs were managed with IMiD discontinuation and steroids, resolving in few weeks, except for Grave's disease and polymiositis.Keywords: multiple myeloma, lenalidomide, Thalidomode, autoimmune diseases.
    Leukemia & lymphoma 04/2014; · 2.61 Impact Factor
  • Leukemia and Lymphoma 01/2014; 55(6). · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CLL has been defined as presence of more than 5000 small mature appearing monoclonal B lymphocytes with a specific immunophenotype in peripheral blood. It is a well-known fact that CLL is associated with autoimmune cytopenias. CLL cells are CD5(+) B lymphocytes, and usually are not the "guilty" cells which produce autoantibodies. T cell defect is another characteristic of CLL and the total number of T cells is increased, and there is inversion of the CD4/CD8 ratio. Autoimmune hemolytic anemia (AIHA) is the most common autoimmune complication of CLL and has been reported in 10-25% of CLL patients. However, the stage-adjusted estimated rate of AIHA in CLL is about 5%. Conversely, CLL is three times more common in patients who present with AIHA. Direct agglutinin test (DAT) is positive in 7-14% of CLL patients but AIHA may also occur in DAT negative patients. Autoimmune thrombocytopenia (AIT) is the second most common complication of CLL and has been reported in 2-3% of patients. DAT is positive in AIT but presence of antiplatelet antibodies is neither diagnostic nor reliable. Autoimmune neutropenia (AIN) and pure red cell aplasia (PRCA) are very rare complications of CLL and like other autoimmune complications of CLL may occur at any clinical stage. It is believed that most case reports of AIN and PRCA in CLL actually belong to large granular lymphocytic leukemia (LGL). Non-hematologic autoimmune complications of CLL including cold agglutinin disease (CAD), paraneoplastic pemphigus (PNP), acquired angioedema, and anti-myelin associated globulin are rare. Before starting any treatment, clinicians should distinguish between autoimmune cytopenias and massive bone marrow infiltration since autoimmune complications of CLL are not necessarily equal to advanced disease with poor prognosis. According to IWCLL guideline, steroids are the mainstay of treatment of simple autoimmunity. Intravenous immunoglobulin (IVIg), cyclosporine, and rituximab are used in complex, steroid refractory cases. Monotherapy with purine analogues and alkylating agents should be avoided as they may increase CLL associated autoimmune complications.
    Mediterranean Journal of Hematology and Infectious Diseases 01/2013; 5(1):e2013068.

Full-text (2 Sources)

Download
39 Downloads
Available from
May 27, 2014